Effectiveness and safety of antiemetic aprepitant in japanese patients receiving high-dose chemotherapy prior to autologous hematopoietic stem cell transplantation

Biological and Pharmaceutical Bulletin

Volumn 36, Issue 5, 2013, Pages 819-824

  Uchida, Mayako ^a   Ikesue, Hiroaki ^a   Miyamoto, Toshihiro ^b   Kato, Koji ^b   Suetsugu, Kimitaka ^a   Ichinose, Kimiko ^a   Hiraiwa, Hiromi ^a   Sakurai, Asako ^a   Takenaka, Katsuto ^b   Muta, Tsuyoshi ^b   Iwasaki, Hiromi ^a   Teshima, Takanori ^a   Shiratsuchi, Motoaki ^b,c   Egashira, Nobuaki ^a   Akashi, Koichi ^b   Oishi, Ryozo ^a  

^a KYUSHU UNIVERSITY HOSPITAL   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Antiemetic effect; Aprepitant; Autologous hematopoietic stem cell transplantation; High dose chemotherapy; Safety

Indexed keywords

APREPITANT; CARBOPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; ETOPOSIDE; GRANISETRON; HYDROXYZINE; MELPHALAN; METOCLOPRAMIDE; RANIMUSTINE; SEROTONIN 3 ANTAGONIST;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; ELECTRONIC MEDICAL RECORD; FEMALE; FLUSHING; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; INSOMNIA; JAPANESE; LEUKEMIA; MALAISE; MALE; MULTIPLE MYELOMA; NAUSEA; NONHODGKIN LYMPHOMA; RETROSPECTIVE STUDY; SIDE EFFECT; SORE THROAT; STOMATITIS; VOMITING;

ADULT; AGED; ANTIEMETICS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; GRANISETRON; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MORPHOLINES; NAUSEA; NEUROKININ-1 RECEPTOR ANTAGONISTS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VOMITING; YOUNG ADULT;

EID: 84876926679     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b12-01012     Document Type: Article

References (30)

1. Hesketh PJ. Chemotherapy-induced nausea and vomiting. N. Engl. J. Med., 358, 2482-2494 (2008).
2. Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E, Bria E, Clark-Snow RA, Espersen BT, Feyer P, Grunberg SM, Hesketh PJ, Jordan K, Kris MG, Maranzano E, Molassiotis A, Morrow G, Olver I, Rapoport BL, Rittenberg C, Saito M, Tonato M, Warr D, ESMO/MASCC Guidelines Working Group. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann. Oncol., 21 (Suppl. 5), v232-v243 (2010).
3. National Comprehensive Cancer Network (NCCN). "NCCN Clinical Practice Guidelines in Oncology. Antiemesis. V.1.2012.": 〈http://www.nccn.org/professionals/physician-gls/pdf/antiemesis.pdf〉, cited 9 October, 2012.
4. Einhorn LH, Grunberg SM, Rapoport B, Rittenberg C, Feyer P. Antiemetic therapy for multiple-day chemotherapy and additional topics consisting of rescue antiemetics and high-dose chemotherapy with stem cell transplant: review and consensus statement. Support. Care Cancer, 19 (Suppl. 1), S1-S4 (2011).
5. Abbott B, Ippoliti C, Hecth D, Bruton J, Whaley B, Champlin R. Granisetron (Kytril) plus dexamethasone for antiemetic control in bone marrow transplant patients receiving highly emetogenic chemotherapy with or without total body irradiation. Bone Marrow Transplant., 25, 1279-1283 (2000).
6. Ballen KK, Hesketh AM, Heyes C, Becker PS, Emmons RV, Fogarty K, LaPointe J, Liu Q, Hsieh CC, Hesketh PJ. Prospective evaluation of antiemetic outcome following high-dose chemotherapy with hematopoietic stem cell support. Bone Marrow Transplant., 28, 1061-1066 (2001).
7. Matsuoka S, Okamoto S, Watanabe R, Mori T, Nagayama H, Hamano Y, Yokoyama K, Takayama N, Ikeda Y. Granisetron plus dexamethasone versus granisetron alone in the prevention of vomiting induced by conditioning for stem cell transplantation: a prospective randomized study. Int. J. Hematol., 77, 86-90 (2003).
8. Walsh T, Morris AK, Holle LM, Callander N, Bradshaw P, Valley AW, Clark G, Freytes CO. Granisetron vs. ondansetron for prevention of nausea and vomiting in hematopoietic stem cell transplant patients: results of a prospective, double-blind, randomized trial. Bone Marrow Transplant., 34, 963-968 (2004).
9. Musso M, Scalone R, Crescimanno A, Bonanno V, Polizzi V, Porretto F, Bianchini C, Perrone T. Palonosetron and dexamethasone for prevention of nausea and vomiting in patients receiving high-dose chemotherapy with auto-SCT. Bone Marrow Transplant., 45, 123-127 (2010).
10. Giralt SA, Mangan KF, Maziarz RT, Bubalo JS, Beveridge R, Hurd DD, Mendoza FL, Rubenstein EB, DeGroot TJ, Schuster MW. Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantation. Ann. Oncol., 22, 939-946 (2011).
11. de Wit R, Herrstedt J, Rapoport B, Carides AD, Carides G, Elmer M, Schmidt C, Evans JK, Horgan KJ. Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. J. Clin. Oncol., 21, 4105-4111 (2003).
12. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie Ma G, Eldridge K, Hipple A, Evans JK, Horgan KJ, Lawson F, Aprepitant Protocol 054 Study Group. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer, 97, 3090-3098 (2003).
13. Gralla RJ, de Wit R, Herrstedt J, Carides AD, Ianus J, Guoguang-Ma J, Evans JK, Horgan KJ. Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III randomized clinical trials. Cancer, 104, 864-868 (2005).
14. Basch E, Prestrud AA, Hesketh PJ, Kris MG, Feyer PC, Somerfield MR, Chesney M, Clark-Snow RA, Flaherty AM, Freundlich B, Morrow G, Rao KV, Schwartz RN, Lyman GH, American Society of Clinical Oncology. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J. Clin. Oncol., 29, 4189-4198 (2011).
15. Paul B, Trovato JA, Thompson J, Badros AZ, Goloubeva O. Efficacy of aprepitant in patients receiving high-dose chemotherapy with hematopoietic stem cell support. J. Oncol. Pharm. Pract., 16, 45-51 (2010).
16. Jordan K, Jahn F, Jahn P, Behlendorf T, Stein A, Ruessel J, Kegel T, Schmoll HJ. The NK-1 receptor-antagonist aprepitant in high-dose chemotherapy (high-dose melphalan and high-dose T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination. Bone Marrow Transplant., 46, 784-789 (2011).
17. Pielichowski W, Barzal J, Gawronski K, Mlot B, Oborska S, Wasko-Grabowska A, Rzepecki P. A triple-drug combination to prevent nausea and vomiting following BEAM chemotherapy before autologous hematopoietic stem cell transplantation. Transplant. Proc., 43, 3107-3110 (2011).
18. Stiff PJ, Fox-Geiman MP, Kiley K, Rychlik K, Parthasarathy M, Fletcher-Gonzalez D, Porter N, Go A, Smith SE, Rodriguez TE. Prevention of nausea and vomiting associated with stem cell transplantation: results of a prospective, randomized trial of aprepitant used with highly emetogenic preparative regimens. Biol. Blood Marrow Transplant., 19, 49-55 (2013).
19. Schimmer BP, Parker KL. Adrenocorticotropic hormone; Adrenocortical steroids and their synthetic analogs; Inhibitors of the synthesis and actions of adrenocortical hormones. Goodman & Gilman's the pharmacological basis of therapeutics. (Brunton LL, Lazo JS, Parker K ed.) Vol. 11, McGraw-Hill, New York, pp. 1587-1612 (2006).
20. Holmberg LA, Boeckh M, Hooper H, Leisenring W, Rowley S, Heimfeld S, Press O, Maloney DG, McSweeney P, Corey L, Maziarz RT, Appelbaum FR, Bensinger W. Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation. Blood, 94, 4029-4035 (1999).
21. Uchida M, Ikesue H, Kato K, Ichinose K, Hiraiwa H, Sakurai A, Takenaka K, Iwasaki H, Miyamoto T, Teshima T, Egashira N, Akashi K, Oishi R. Antiemetic effectiveness and safety of aprepitant in patients with hematologic malignancy receiving multiday chemotherapy. Am. J. Health Syst. Pharm., 70, 343-349 (2013).
22. López-Jiménez J, Martín-Ballesteros E, Sureda A, Uralburu C, Lorenzo I, del Campo R, Fernández C, Calbacho M, García-Belmonte D, Fernández G. Chemotherapy-induced nausea and vomiting in acute leukemia and stem cell transplant patients: results of a multicenter, observational study. Haematologica, 91, 84-91 (2006).
23. Mattiuzzi GN, Cortes JE, Blamble DA, Bekele BN, Xiao L, Cabanillas M, Borthakur G, O'Brien S, Kantarjian H. Daily palonosetron is superior to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia. Cancer, 116, 5659-5666 (2010).
24. Japan Clinical Oncology Group (JCOG). "Common Terminology Criteria for Adverse Events (CTCAE), version 4.0-JCOG.": 〈http://www.jcog.jp/ doctor/tool/CTCAEv4J-20111217.pdf〉, cited 9 October, 2012.
25. Majumdar AK, McCrea JB, Panebianco DL, Hesney M, Dru J, Constanzer M, Goldberg MR, Murphy G, Gottesdiener KM, Lines CR, Petty KJ, Blum RA. Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe. Clin. Pharmacol. Ther., 74, 150-156 (2003).
26. Aapro MS, Walko CM. Aprepitant: drug-drug interactions in perspective. Ann. Oncol., 21, 2316-2323 (2010).
27. Glotzbecker B, Duncan C, Alyea E 3rd, Campbell B, Soiffer R. Important drug interactions in hematopoietic stem cell transplantation: what every physician should know. Biol. Blood Marrow Transplant., 18, 989-1006 (2012).
28. Ono Pharmaceutical. EMEND (aprepitant) package insert. Osaka, Japan (2012).
29. Bubalo JS, Cherala G, McCune JS, Munar MY, Tse S, Maziarz R. Aprepitant pharmacokinetics and assessing the impact of aprepitant on cyclophosphamide metabolism in cancer patients undergoing hematopoietic stem cell transplantation. J. Clin. Pharmacol., 52, 586-594 (2012).
30. Walko CM, Combest AJ, Spasojevic I, Yu AY, Bhushan S, Hull JH, Hoskins J, Armstrong D, Carey L, Collicio F, Dees EC. The effect of aprepitant and race on the pharmacokinetics of cyclophosphamide in breast cancer patients. Cancer Chemother. Pharmacol., 69, 1189-1196 (2012).